PCAT1, ANRIL, H19, ANGPTL1‐3, or NEAT1 upregulation induced myeloma cells insensitive to bortezomib, whereas CRNDE overexpression leads to dexamethasone tolerance. Here, PCAT1 is linked to plasma cell myeloma.